Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas.
Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm(2) and 3 cm(2). Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host.
Theys
J
J
Laboratory of Bacteriology, Rega Institute for Medical Research, Leuven, Belgium.
Landuyt
W
W
Nuyts
S
S
Van Mellaert
L
L
Bosmans
E
E
Rijnders
A
A
Van Den Bogaert
W
W
van Oosterom
A
A
Anné
J
J
Lambin
P
P
D000818:Animals; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents / Q000008:administration & dosage; D000907:Antibodies, Bacterial / Q000032:analysis; D003013:Clostridium / Q000187:drug effects / Q000254:growth & development* / Q000276:immunology; D003015:Clostridium Infections / Q000188:drug therapy / Q000382:microbiology*; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage; D051381:Rats; D012208:Rhabdomyosarcoma / Q000098:blood supply / Q000382:microbiology* / Q000628:therapy; D013171:Spores, Bacterial / Q000254:growth & development*; D013267:Stilbenes / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000907:Antibodies, Bacterial; D013267:Stilbenes; D008795:Metronidazole; C058728:fosbretabulin